Closing of the third stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (July 2nd, 2019) – Further to BioLight’s announcement dated July 1st, 2019, BioLight hereby announces closing of the third stage of the binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Agreement”). The value date of said closing, as agreed between the Parties to the Agreement, is June 30, 2019.

Link to the complete article

Link to Newsroom

Comments are closed.